Description
Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.
Product Availability: In Stock.
Transfection Reagent for NCI-N87 Cells (Gastric Carcinoma Cells, CRL-5822)
-
Two component formulation enhances lipid mediated transfection efficiency
-
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
-
Kit includes Transfection Enhancer reagent and recommended transfection protocol
-
High transfection efficacy in the presence of serum
-
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
-
Reproducible transfection results
-
Works well for standard reverse transfection and high-throughput applications
-
Download in vitro NCI-N87 transfection protocol: [PDF]
- Download NCI-N87 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for NCI-N87 cells transfection kit: [PPT]
-
Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Product Description:
High efficiency transfection reagent for NCI-N87cell line used as an experimental model to study gastric function, cell biology, and gastric cancer.
Transfection Protocol and SDS:
Download Altogen Biosystems NCI-N87 Transfection Protocol: [PDF]
Download SDS: [PDF]
NCI-N87 Cell Line:
NCI-N87 is a human gastric cancer cell line that was originally derived from a patient with poorly differentiated adenocarcinoma of the stomach. NCI-N87 cells are characterized by their high expression of the human epidermal growth factor receptor 2 (HER2), which is a protein that promotes cell growth and division. These cells also have mutations in the TP53 and APC genes, which are commonly found in gastric cancer and contribute to the development and progression of the disease. Researchers have used NCI-N87 cells to study various aspects of gastric cancer biology, including the signaling pathways that drive tumor growth and metastasis, the mechanisms of drug resistance, and the development of new therapeutic agents targeting HER2. This cell line has also been used to study the role of TP53 and APC in gastric cancer development and to test the efficacy of novel drugs targeting these pathways.
According to the American Cancer Society (ACS), gastric cancer was the most common cause of cancer fatalities in the United States until the late 1930s. However, in less developed countries with a general lack of access to refrigerated food storage, it remains a high mortality disease. Human tumor cell lines have proven to be invaluable models for studying cancer causes and properties. The NCI-N87 epithelial cell line was established from the stomach tissue of a male patient with gastric carcinoma, also known as stomach cancer. NCI-N87 cells have been derived from a metastatic site located in the liver. Also, the NCI-N87 cell line has been tested positive for myc and ERBB2 oncogenes. NCI-N87 cells express carcinoembryonic antigen (CEA) and TAG 72 surface glycoproteins. They were also found to express receptors for muscarinic cholinergic agents. In addition to being used in stomach cancer research, the NCI-N87 cell line is highly utilized in transfection. Commercially available transfection reagent kits can be ordered from Altogen Biosystems, including a two-component formulation NCI-N87 transfection reagent for gastric carcinoma cells.
Cell line mutations:
| CNBD1 | 168975 | 37 | 8 | 88365898 | 88365898 | Missense_Mutation | SNP | T | G |
| CACNA1B | 774 | 37 | 9 | 140772533 | 140772533 | Missense_Mutation | SNP | G | T |
| MUC16 | 94025 | 37 | 19 | 9070919 | 9070919 | Silent | SNP | A | G |
| KIR3DL2 | 3812 | 37 | 19 | 55378031 | 55378031 | Missense_Mutation | SNP | G | A |
| TTN | 7273 | 37 | 2 | 179666974 | 179666974 | Silent | SNP | G | A |
| GMPPA | 29926 | 37 | 2 | 220371039 | 220371039 | Missense_Mutation | SNP | G | A |
| TMEM63B | 55362 | 37 | 6 | 44103069 | 44103069 | Missense_Mutation | SNP | C | T |
| ABCB1 | 5243 | 37 | 7 | 87150134 | 87150134 | Missense_Mutation | SNP | T | C |
| NOC2L | 26155 | 37 | 1 | 881827 | 881827 | Missense_Mutation | SNP | G | C |
| PLEKHN1 | 84069 | 37 | 1 | 906355 | 906355 | Missense_Mutation | SNP | G | T |
| ERRFI1 | 54206 | 37 | 1 | 8064608 | 8064608 | Missense_Mutation | SNP | T | C |
Data:
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NCI-N87 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A in NCI-N87 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NCI-N87 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides safety and efficacy preclinical research services. GLP-compliant studies for IND applications, and drug development, including over 90 in-house validated xenograft models, safety toxicology, etc (visit AltogenLabs.com).
Volume Options:
- 0.5 ml (Catalog #6870)
- 1.5 ml (Catalog #6871)
- 1.5 ml CRISPR (Catalog #2183)
- 8.0 ml (Catalog #7072)
Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.
Product Availability: In Stock.